AACR 2025 - Advancing Oncology Research and Minimal Residual Disease Detection with Inocras’s Whole Genome Cancer Platform

Introduction Our speakers and agenda Introducing Inocras Applying whole genome to cancer profiling Dx and MRD test What do you see with whole genome? CancerVision™. Curating vast WG data to actionable insights CancerVision: Head-to-head comparison with TSO500; TE-WGS presents additional insights not captured in standard panel sequencing CancerVision: More accurate genome-wide markers, reducing false positive significantly CancerVision vs. Panel: Evaluating the Added Clinical Value of WGS in Prostate Cancer CancerVision Detected 96% of Clinically Reported Variants—With Added Insights Uncovering Clinically Actionable with CancerVision MRDVisionTM: Whole genome x whole genome approach MRDVision: Analytical validation methodology and results MRDVision Clinical validation - as low as 1 ppm sensitivity MRDVision Clinical validation - Orthogonal study results MRDVision Clinical validation - Orthogonal study results MRDVision delivers accuracy, affordability, and more WGS data